Sage Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Sage Therapeutics, Inc. has successfully completed its acquisition by Supernus Pharmaceuticals, Inc. through a tender offer and subsequent merger, leading to its delisting from The Nasdaq Global Market.
Sage Therapeutics announced robust second quarter 2025 financial results, highlighted by significant ZURZUVAE revenue growth, as it progresses towards its acquisition by Supernus Pharmaceuticals.
Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Sage Therapeutics, Inc. for an upfront cash payment of $8.50 per share plus a contingent value right of up to $3.50 per share, totaling up to $12.00 per share, aiming to expand its CNS product offerings and achieve significant synergies.
Sage Therapeutics, Inc. announced that its stockholders approved the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, the non-binding advisory vote on executive compensation, and an amendment to its 2014 Employee Stock Purchase Plan at its Annual Meeting on June 11, 2025.
Sage Therapeutics announces Q1 2025 financial results, highlighting growth in ZURZUVAE revenue and shipments for postpartum depression treatment, while a strategic alternatives review remains ongoing.
Laura Gault, M.D., Ph.D., Chief Medical Officer of Sage Therapeutics, has resigned effective March 21, 2025, to pursue a new opportunity.
Sage Therapeutics announces its Q4 and full-year 2024 financial results, highlighting strong ZURZUVAE growth and a cash runway extending to mid-2027.
Sage Therapeutics' board has initiated a review of strategic options, including a potential sale, after rejecting Biogen's $7.22 per share acquisition proposal.
Sage Therapeutics acknowledges receiving an unsolicited, non-binding acquisition proposal from Biogen to acquire all outstanding shares not already owned by Biogen for $7.22 per share.
Dr. Jeffrey M. Jonas, a member of Sage Therapeutics' Board of Directors, has announced his retirement, effective December 1, 2024.
Sage Therapeutics' Phase 2 DIMENSION study of dalzanemdor for Huntington's Disease cognitive impairment did not meet its primary endpoint, leading to the halt of further development.
Sage Therapeutics has entered into separation agreements with its former Chief Financial Officer and General Counsel as part of a previously announced reorganization.
Sage Therapeutics announced its third quarter 2024 financial results, highlighted by a 49% increase in ZURZUVAE collaboration revenue and strategic pipeline adjustments.
Sage Therapeutics is reorganizing its business, reducing its workforce by approximately 33%, and making leadership changes to support the launch of ZURZUVAE and focus on pipeline development.
Sage Therapeutics' dalzanemdor (SAGE-718) did not meet its primary endpoint in a Phase 2 trial for Alzheimer's disease, leading to the cessation of further development in this indication.
Biogen has terminated its collaboration agreement with Sage Therapeutics regarding the SAGE-324 molecule, effective February 17, 2025, following negative Phase 2 trial results.
Sage Therapeutics announced its second quarter 2024 financial results, highlighting growth in ZURZUVAE sales and mixed progress in its pipeline development.
A Phase 2 study of SAGE-324 for essential tremor did not demonstrate a statistically significant dose-response relationship, leading to the termination of further development for this indication.
Sage Therapeutics' stockholders approved the 2024 Equity Incentive Plan and elected two directors at their annual meeting on June 10, 2024.
Sage Therapeutics' Phase 2 SURVEYOR study met its primary endpoint, demonstrating a statistically significant difference in cognitive function between healthy participants and those with Huntington's Disease.
Sage Therapeutics announced its first quarter 2024 financial results, highlighting encouraging initial demand for ZURZUVAE and progress in its pipeline.
Sage Therapeutics has amended its 2016 Inducement Equity Plan, reducing the number of shares available for issuance and ceasing future awards under the plan after April 16, 2024.
Sage Therapeutics' dalzanemdor did not meet its primary endpoint in a Phase 2 trial for mild cognitive impairment in Parkinson's disease, but the company remains optimistic about ongoing trials for Huntington's and Alzheimer's diseases.
Sage Therapeutics announces that board member Steven Paul will retire at the company's 2024 annual meeting.
Sage Therapeutics announced its Q4 and full year 2023 financial results, highlighting the commercial launch of ZURZUVAE for postpartum depression and progress in its clinical pipeline.
Sage Therapeutics stockholders approved a one-time stock option exchange program for non-executive officer employees at a special meeting held on January 31, 2024.
Sage Therapeutics has entered into a lease agreement for a new corporate headquarters at 55 Cambridge Parkway, relocating from its current location upon lease expiration.